Treatment with Noripurum EV<sup>®</sup>is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia

Venturieri, Maissara Obara; Komati, Juliana T S; Lopes, Letícia H.C.; Sdepanian, Vera Lúcia

doi:10.1080/00365521.2019.1570326

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Children with iron deficiency resulting from IBD (which was treated with the anti-inflammatory drug infliximab) displayed significantly increased mean ferritin, TSAT, and Hb levels after treatment with iron sucrose, and a higher proportion of these children also had normalized ferritin, TSAT, and Hb levels versus historical control data from the same patients [126]. Similarly, in a cohort of children with IBD (mean age 11.3 years) who were mildly to severely anemic, iron sucrose (median dose 638.4 mg) increased Hb levels in all 16 patients, and ferritin and TSAT levels were also statistically higher post-infusion [127]. Another study in children with IBD showed that correction of iron-deficiency anemia using IV iron sucrose therapy was significantly correlated with better health-related quality of life scores [128].…”

Section: Pediatric Populationsmentioning

confidence: 73%

“…The safety profile is therefore well established in many different patient groups, including CKD, GI disorders, women’s health disorders, oncology, cardiology, and for patient blood management (Tables 2 , 3 , 4 , 5 , 6 , 7 ). To date, more than 50 published clinical studies, covering numerous patient populations, have reported safety outcomes with administration of iron sucrose; 18 of these studies have been reported in the last 5 years [ 40 , 46 , 47 , 50 , 52 , 53 , 58 , 66 , 73 , 74 , 111 , 113 , 114 , 126 , 127 , 129 – 131 ].…”

Section: Safety and Tolerability Of Iron Sucrosementioning

confidence: 99%

See 1 more Smart Citation

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

et al. 2020

View full text Add to dashboard Cite

Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient populations, this can be treated effectively with oral iron supplementation; but in patients who are unable to take or who do not respond to oral iron therapy, intravenous iron administration is recommended. Furthermore, in certain conditions, such as end-stage kidney disease, chronic heart failure, and inflammatory bowel disease, intravenous iron administration has become first-line treatment. One of the first available intravenous iron preparations is iron sucrose (Venofer ® ), a nanomedicine that has been used clinically since 1949. Treatment with iron sucrose is particularly beneficial owing to its ability to rapidly increase hemoglobin, ferritin, and transferrin saturation levels, with an acceptable safety profile. Recently, important new data relating to the use of iron sucrose, including the findings from the landmark PIVOTAL trial in patients with end-stage kidney disease, have been reported. Several years ago, a number of iron sucrose similars became available, although there have been concerns about the clinical appropriateness of substituting the original iron sucrose with an iron sucrose similar because of differences in efficacy and safety. This is a result of the complex and unique physicochemical properties of nanomedicines such as iron sucrose, which make copying the molecule difficult and problematic. In this review, we summarize the evidence accumulated during 70 years of clinical experience with iron sucrose in terms of efficacy, safety, and cost-effectiveness.

show abstract

Section: Pediatric Populationsmentioning

confidence: 73%

Section: Safety and Tolerability Of Iron Sucrosementioning

confidence: 99%

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It would be discussed that the infliximab group was worst about the IBD compared to the conventional group and that even though the activity index indicated that the infliximab group was on remission, the anemia was not solved. So, in some patients, who presented iron deficiency anemia, the intravenous iron therapy, as shown by Venturieri, et al study (43) , would be indicated even though the patient presented normal iron absorption.…”

Section: Discussionmentioning

confidence: 97%

Body Iron Status Indicators and Inflammation Indicators During Inflammatory Bowel Disease Therapy in Children and Adolescentes

Corrêa

Sdepanian

2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: The treatment of patients with inflammatory bowel disease (IBD) consists of the induction and maintenance remission of the disease. Iron status indicators would be useful for the diagnosis of iron deficiency anemia, whereas the inflammation indicators would be for the diagnosis of chronic disease anemia. OBJECTIVE: To assess body iron status indicators and inflammation indicators during the treatment of IBD, consisted of conventional or infliximab therapy in children and adolescents. METHODS: A case-control study of a sample of 116 individuals, of which 81 patients with IBD, 18 of them receiving conventional therapy, 20 infliximab therapy, and 43 who were in remission of the disease, and 35 healthy (control group) children and adolescents. Iron status and inflammation indicators were investigated at baseline, and 2 and 6 months of both therapies - conventional and infliximab. RESULTS: The mean age was 12.1±4.3 years. At baseline, both groups - conventional therapy and infliximab - presented significant differences in most markers studied compared to the control group. After 2 months of conventional therapy, hemoglobin and serum iron levels were lower than those of the control group; and red cells distribution width (RDW), total iron-binding capacity, transferrin receptor/ferritin ratio, and interleukin-6 were higher than the control group. After 2 months of infliximab treatment, hemoglobin and serum iron levels were lower than those of the control group; and RDW, soluble transferrin receptor, soluble transferrin receptor/ferritin ratio, and interleukin-6 were higher than the control group. After 6 months of conventional therapy, hemoglobin and serum iron levels were lower than those of the control group, and RDW and interleukin-6 were higher than those of the control group. After 6 months of infliximab treatment, the hemoglobin and serum iron levels were lower than the control group, and RDW, soluble transferrin receptor, soluble transferrin receptor/ferritin ratio, erythrocyte sedimentation rate, and platelets were higher than the control group. Regarding patients under treatment for at least one year (remission group), all markers studied, except transferrin, were similar to the control group. CONCLUSION: In conclusion, there were some contradictions among the different body iron status indicators and inflammation indicators at two and 6 months of treatment with conventional and infliximab therapy, however after one year of treatment, as shown by the remission group, all indicators studied, except transferrin, were similar to healthy children and adolescents.

show abstract

Treatment with Noripurum EV^®is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia

Cited by 2 publications

References 26 publications

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Body Iron Status Indicators and Inflammation Indicators During Inflammatory Bowel Disease Therapy in Children and Adolescentes

Contact Info

Product

Resources

About

Treatment with Noripurum EV®is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia

Cited by 2 publications

References 26 publications

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Body Iron Status Indicators and Inflammation Indicators During Inflammatory Bowel Disease Therapy in Children and Adolescentes

Contact Info

Product

Resources

About

Treatment with Noripurum EV^®is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia